University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

March 14, 2016

Finding is relevant to certain cancers of the blood.

February 17, 2016

Despite advances, the majority of patients receiving targeted therapies do not experience radiographic responses, and nearly all patients who initially benefit develop resistance in less than two years.

November 03, 2015

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

August 30, 2015

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

July 16, 2015

Focus will be on Wisconsin Center's innovative research centers and impact on local communities.

July 06, 2015

Stephen Rosenberg, MD, University of Wisconsin School of Medicine and Public Health, discusses a study examining if online patient information provided by National Cancer Institute (NCI)-designated cancer center websites is too complex for general readership.

June 23, 2015

Ruth M. O'Regan, MD, discusses two of her studies in HER2-positive breast cancer presented at ASCO 2015.

June 17, 2015

Ruth O'Regan, MD, medical oncology, Breast Cancer Clinic, University of Wisconsin Carbone Cancer Center, faculty, University of Wisconsin School of Medicine and Public Health, evaluates the Breast Cancer Index in patients with HER2-positive, HR-positive breast cancer for risk of late recurrence and endocrine benefit.

June 13, 2011

Currently, more than 250 physicians and scientists work in concert to provide state-of- the art diagnosis, treatment, and aftercare for the more than 20,000 patients seen each year at the UW hospitals, clinics, and affiliate clinical facilities